TRCT
IKT icon

Tower Research Capital (TRC)’s Inhibikase Therapeutics IKT Stock Holding History

Tower Research Capital (TRC)’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$29.2K Buy
17,354
+10,845
+167% +$19.3K ﹤0.01% 3196
2025
Q4 		$13.3K Sell
6,509
-537
-8% -$855 ﹤0.01% 3412
2025
Q3 		$11.4K Buy
7,046
+6,946
+6,946% +$12K ﹤0.01% 3883
2025
Q2 		$195 Buy
+100
New +$196 ﹤0.01% 5108
2024
Q4 		– Sell
-4,057
Closed -$5.27K – 5832
2024
Q3 		$5.27K Sell
4,057
-1,679
-29% -$2.25K ﹤0.01% 4299
2024
Q2 		$6.94K Buy
5,736
+2,965
+107% +$5.11K ﹤0.01% 4519
2024
Q1 		$5.99K Sell
2,771
-3,148
-53% -$6.95K ﹤0.01% 4456
2023
Q4 		$7.52K Buy
5,919
+3,719
+169% +$3.85K ﹤0.01% 4610
2023
Q3 		$3.06K Buy
2,200
+216
+11% +$484 ﹤0.01% 5061
2023
Q2 		$7.16K Sell
1,984
-238
-11% -$887 ﹤0.01% 4613
2023
Q1 		$9K Buy
2,222
+420
+23% +$1.75K ﹤0.01% 4500
2022
Q4 		$5K Buy
1,802
+774
+75% +$3.07K ﹤0.01% 4871
2022
Q3 		$6K Sell
1,028
-1,642
-61% -$8.64K ﹤0.01% 5020
2022
Q2 		$12K Buy
2,670
+2,404
+904% +$14.2K ﹤0.01% 4283
2022
Q1 		$2K Sell
266
-801
-75% -$6.45K ﹤0.01% 5559
2021
Q4 		$10K Buy
1,067
+166
+18% +$1.83K ﹤0.01% 4569
2021
Q3 		$10K Buy
+901
New +$12.2K ﹤0.01% 4318
2021
Q2 		– Sell
-91
Closed -$3K – 5642
2021
Q1 		$3K Buy
+91
New +$3.68K ﹤0.01% 4901

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Tower Research Capital (TRC)'s IKT Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Inhibikase Therapeutics (IKT) stake by 167% in Q1 2026, buying an estimated $19.3K and bringing the position to 17,354 shares worth $29.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3196.

Tower Research Capital (TRC) first reported a position in IKT in Q1 2021 and has held it in 18 quarters since. 104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

  • Tower Research Capital (TRC) held 17,354 shares of Inhibikase Therapeutics worth $29.2K as of Q1 2026.
  • Tower Research Capital (TRC) bought 10,845 Inhibikase Therapeutics shares in Q1 2026, an estimated $19.3K.
  • Inhibikase Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3196 holding.
  • Tower Research Capital (TRC) first reported a position in Inhibikase Therapeutics in Q1 2021 and has held it in 18 quarters since.
  • 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.